Results 151 to 160 of about 41,587 (192)
Inflammatory and neurotoxic risk of atorvastatin in diabetic peripheral neuropathy: TNF-centered evidence integrating network toxicology, scRNA-Seq, and cell validation. [PDF]
Front ChemYang H +9 more
europepmc +1 more source
High-Intensity Atorvastatin and 24-Hour Blood Pressure in Obstructive Sleep Apnea: A Randomized, -Double-Blind, Placebo-Controlled Pilot Study. [PDF]
Am J HypertensBock JM +9 more
europepmc +1 more source
Comprehensive management of a chronic patient in community pharmacy: impact of Comprehensive Medication Management on health outcomes and quality of life. [PDF]
Farm ComunitariosPérez Rodríguez RO +2 more
europepmc +1 more source
Nationwide assessment of community pharmacists' practices and atorvastatin-drug interactions in Egypt. [PDF]
Sci RepMaslub MG +4 more
europepmc +1 more source
ROS-responsive nanocarriers for the delivery of atorvastatin in ischemic MCAO rats promoting neuroprotection. [PDF]
Mater Today BioNagareddy R +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Pharmacotherapy, 2005
The introduction of statins has drastically changed the treatment and prevention of atherosclerotic vascular disease. By lowering lipid levels and reducing the risk of coronary heart disease, these drugs are among the most effective at reducing morbidity and mortality available to clinical practice.
Sander I, van Leuven +1 more
openaire +2 more sources
The introduction of statins has drastically changed the treatment and prevention of atherosclerotic vascular disease. By lowering lipid levels and reducing the risk of coronary heart disease, these drugs are among the most effective at reducing morbidity and mortality available to clinical practice.
Sander I, van Leuven +1 more
openaire +2 more sources
Drugs, 2007
Extensive data are available on the safety of atorvastatin from randomised clinical trials, postmarketing analyses and reports to regulatory agencies. Atorvastatin is generally well tolerated across the range of therapeutic dosages, with the exception of a slightly higher rate of liver enzyme elevations with atorvastatin 80 mg/day which does not appear
openaire +3 more sources
Extensive data are available on the safety of atorvastatin from randomised clinical trials, postmarketing analyses and reports to regulatory agencies. Atorvastatin is generally well tolerated across the range of therapeutic dosages, with the exception of a slightly higher rate of liver enzyme elevations with atorvastatin 80 mg/day which does not appear
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2001
Atorvastatin (Lipitor, Pfizer) is a safe and effective 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin). It is the most potent currently available statin in terms of lowering low-density lipoprotein (LDL) and total cholesterol levels.
openaire +3 more sources
Atorvastatin (Lipitor, Pfizer) is a safe and effective 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin). It is the most potent currently available statin in terms of lowering low-density lipoprotein (LDL) and total cholesterol levels.
openaire +3 more sources